Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
The non-benzodiazepine GABA A receptor modulators (‘Z-drugs’) — zaleplon, zolpidem, zopiclone and eszopiclone — have become the accepted treatments for insomnia where they are available. However, recent randomized, placebo-controlled trials suggest that, for these drugs, there may be particular efficacy and tolerability profiles and distinct clinical outcomes in specific patient populations. This is particularly apparent when hypnotic/ selective serotonin reuptake inhibitor co-therapy is used to treat patients with co-morbid insomnia and psychiatric disorders, as patient recovery appears to be accelerated and enhanced by some drugs but not others. Emerging evidence of why this should be the case is that these hypnotic drugs may differ significantly from each other in their pharmacodynamic and pharmacokinetic profiles. Functional selectivity for specific GABA A receptor subtypes may determine each drug’s clinical attributes, while the pharmacokinetic characteristics of Z-drugs also determine to a large extent how they perform in the clinic. For example, activity at GABA A alpha 1 receptor subtypes may be associated with sedative effects, whereas activity at alpha 2 and alpha 3 receptor subtypes may be associated with anxiolytic and antidepressant effects. In summary, the distinct clinical outcomes of zaleplon, zolpidem, zopiclone and eszopiclone may be explained by each drug’s unique GABA A receptor subunit selectivity and pharmacokinetic profile. Further investigation of GABA A receptor subtype effects would help to increase understanding of current hypnotic drug effects, while knowledge of each drug’s specific binding profile should enable clinicians to tailor treatment to individual patient’s needs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is clinical evidence for the antidepressant effects of subtype selective GABAAR compounds as eszopiclone, a positive GABAAR modulator with postulated selectivity for α2/α3GABAARs [138], has a synergistic effect when given in combination with fluoxetine in patients with depression and insomnia [139].”
From An emerging circuit pharmacology of GABAA receptors (2018) · cites this paper as [138]
In the citing paper
“Eszopiclone is the active isomer of zopiclone but binds preferentially to the α-3 benzodiazepine GABA receptor subtype, which might underpin its particular therapeutic profile. 33”
Citations
Cites
Insomnia: Definition, Prevalence, Etiology, and Consequences
Roth, T. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26929 · Cited by 1,492 · cited 1×
“Insomnia is a condition of perceived inadequate sleep, with patients typically presenting with difficulty falling asleep, difficulty maintaining sleep or poor quality sleep (Roth, 2007).”
BackgroundGABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain
Pirker, S., Schwarzer, C., Wieselthaler, A., Sieghart, W., & Sperk, G. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00442-5 · Cited by 1,344 · cited 3×
“GABAA receptor subunit isoforms demonstrate distinct regional and cellular distribution patterns within the brain (Pirker et al., 2000; Sieghart, 2006), suggesting that the location of each GABAA receptor variant as well as its subunit composition may determine its function.”
BackgroundBenzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172 · cited 1×
“Studies in these mice revealed that sedation, amnesic and anticonvulsant effects of benzodiazepines were significantly attenuated, consistent with these effects being mediated primarily through the alpha 1 subunit (Rudolph et al., 1999; Crestani et al., 2000; McKernan et al., 2000).”
BackgroundMolecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · cited 1×
“Mice with point-mutated alpha 2 GABA receptor subunits lack an anxiolytic response to diazepam (Löw et al., 2000) and examination of a murine knock-in has shown that the anxiolytic effect of benzodiazepines is mediated by alpha 2 receptors expressed in the limbic system (Kopp et al., 2004).”
BackgroundMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944 · cited 3×
“In mice it is possible to produce a genetically modified alpha 1 subunit that is insensitive to benzodiazepines but shows normal GABA sensitivity (McKernan et al., 2000).”
BackgroundJansson-Fröjmark, M., & Lindblom, K. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.10.016 · Cited by 646 · cited 1×
“(2006); Krystal et al. (2008); Walsh et al.”
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630 · cited 3×
“In contrast to findings reported for racemic zopiclone, eszopiclone provides benefits in next-day functioning and alertness (Krystal et al., 2003; Rosenberg et al., 2005; Roth et al., 2005; Scharf, 2006).”
BackgroundResultCollinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 2×
“, 2007), and enhance cognition, learning and memory in rodents (Collinson et al., 2002; Dawson et al., 2006).”
BackgroundMeta-analysis of benzodiazepine use in the treatment of insomnia.
(2000) · PubMed Central · Cited by 613
Sivertsen, B., Omvik, S., Pallesen, S., Bjorvatn, B., Havik, O. E., Kvale, G., Nielsen, G. H., & Nordhus, I. H. (2006) · JAMA · doi:10.1001/jama.295.24.2851 · Cited by 589 · cited 1×
“Racemic zopiclone reduces sleep latency and increases total sleep time (TST) (Ngen and Hassan, 1990; Ponciano et al., 1990; Noble et al., 1998; Sivertsen et al., 2006) (Table 6).”
BackgroundRudolph, U., & Möhler, H. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121429 · Cited by 519 · cited 2×
“Hypnotic effects are also associated with activity at the alpha 2 subunit (Rudolph and Möhler, 2004).”
Backgroundγ‐Aminobutyric AcidA Receptor α5‐Subunit Creates Novel Type II Benzodiazepine Receptor Pharmacology
Pritchett, D. B., & Seeburg, P. H. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01237.x · Cited by 503 · cited 1×
“Zolpidem’s affinity for alpha 5 is exceptionally low (negligible in practice), and its efficacy at this subtype is also minimal (Pritchett and Seeburg, 1990).”
BackgroundHevers, W., & Lüddens, H. (1998) · Molecular Neurobiology · doi:10.1007/bf02741459 · Cited by 489 · cited 1×
“GABAA receptors are complex, highly heterogeneous pentameric clusters of membrane-spanning proteins found throughout the central nervous system (Hevers and Lüddens, 1998).”
BackgroundFunctional domains of GABAA receptors
Smith, G. B., & Olsen, R. W. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89009-4 · Cited by 489 · cited 1×
“The most common pentameric receptor configuration is two alpha subunits, two beta subunits and one gamma subunit and the most common receptor subtypes are a1b2g2, a2b3g2 and a3b3g2 (Smith and Olsen, 1995).”
BackgroundFava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480 · cited 3×
“In a study of patients with insomnia co-morbid with GAD, zolpidem CR/escitalopram co-therapy resulted in significant sleep improvements compared with monotherapy.”
ResultRoth, T., Jaeger, S., Jin, R., Kalsekar, A., Stang, P. E., & Kessler, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.039 · Cited by 422 · cited 2×
“As many as 80% of patients with insomnia report comorbid psychiatric symptoms (Stewart et al., 2006), and insomnia is known to be a risk factor for both depression and anxiety disorders (Roth et al., 2006a; Janssen-Fröjmark and Lindblom, 2008).”
BackgroundThe morbidity of insomnia uncomplicated by psychiatric disorders
Weissman, M. M., Greenwald, S., Niño-Murcia, G., & Dement, W. C. (1997) · General Hospital Psychiatry · doi:10.1016/s0163-8343(97)00056-x · Cited by 415 · cited 1×
“Insomnia in the presence of psychiatric disorders imposes a significant extra burden on patients, who make greater use of healthcare services than patients with either of these conditions alone (Weissman et al., 1997).”
BackgroundHomeostatic, circadian, and emotional regulation of sleep
Saper, C. B., Cano, G., & Scammell, T. E. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20770 · Cited by 403 · cited 1×
“This mutual inhibitory system can be considered a ‘flip-flop’ switch that effects sharp transitions between states of consciousness (Saper et al., 2005).”
BackgroundStructure, Pharmacology, and Function of GABAA Receptor Subtypes
Sieghart, W. (2006) · Advances in Pharmacology · doi:10.1016/s1054-3589(06)54010-4 · Cited by 317 · cited 2×
“Elucidation of the GABAA receptor structure has revealed it is composed of five protein subunits and at least 19 distinct subunit isoforms, each encoded by a separate gene, have been identified (Sieghart, 2006).”
BackgroundMechanism of action of the hypnotic zolpidem in vivo
Crestani, F., Martin, J. R., Möhler, H., & Rudolph, U. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703717 · Cited by 307 · cited 1×
“Studies in these mice revealed that sedation, amnesic and anticonvulsant effects of benzodiazepines were significantly attenuated, consistent with these effects being mediated primarily through the alpha 1 subunit (Rudolph et al., 1999; Crestani et al., 2000; McKernan et al., 2000).”
BackgroundEfficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T. (2004) · Current Medical Research and Opinion · doi:10.1185/174234304x15174 · Cited by 294 · cited 5×
“There is no evidence that eszopiclone therapy is associated with any changes in sleep architecture (Zammit et al., 2004).”
BackgroundInfluentialStewart, R., Besset, A., Bebbington, P., Brugha, T., Lindesay, J., Jenkins, R., Singleton, N., & Meltzer, H. (2006) · Sleep · doi:10.1093/sleep/29.11.1391 · Cited by 274 · cited 1×
“As many as 80% of patients with insomnia report comorbid psychiatric symptoms (Stewart et al., 2006), and insomnia is known to be a risk factor for both depression and anxiety disorders (Roth et al., 2006a; Janssen-Fröjmark and Lindblom, 2008).”
BackgroundNoble, S., Langtry, H. D., & Lamb, H. M. (1998) · Drugs · doi:10.2165/00003495-199855020-00015 · Cited by 254 · cited 1×
“Racemic zopiclone reduces sleep latency and increases total sleep time (TST) (Ngen and Hassan, 1990; Ponciano et al., 1990; Noble et al., 1998; Sivertsen et al., 2006) (Table 6).”
BackgroundDrover, D. R. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443040-00002 · Cited by 248
Dias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247 · cited 2×
“, 2005), whereas selective alpha 3 agonism is anxiolytic in mice and primates (Dias et al., 2005).”
BackgroundAn Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
Dawson, G. R., Maubach, K. A., Collinson, N., Cobain, M., Everitt, B. J., MacLeod, A. M., Choudhury, H. I., McDonald, L. M., Pillai, G., Rycroft, W., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092320 · Cited by 241 · cited 1×
“Alpha 5 inverse agonists, which reduce GABA-mediated neurotransmission through this receptor, inhibit the amnestic effects of alcohol in humans (Nutt et al., 2007), and enhance cognition, learning and memory in rodents (Collinson et al., 2002; Dawson et al., 2006).”
BackgroundWalsh, J. K., Krystal, A. D., Amato, D. A., Rubens, R., Caron, J., Wessel, T. C., Schaefer, K., Roach, J., Wallenstein, G., & Roth, T. (2007) · Sleep · doi:10.1093/sleep/30.8.959 · Cited by 239 · cited 2×
“Eszopiclone’s sleep and next-day function improvements are sustained over 6–12 months (Krystal et al., 2003; Roth et al., 2005; Walsh et al., 2007) and there is no significant evidence of tolerance, dependence or rebound insomnia during and after long-term treatment (Zammit et al.”
BackgroundDiazepam-induced changes in sleep: Role of the α1 GABAAreceptor subtype
Tobler, I., Kopp, C., Deboer, T., & Rudolph, U. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111055398 · Cited by 230 · cited 2×
“However, the alpha 1 subtype does not appear to mediate changes on the sleep electroencephalogram (EEG) (Tobler et al., 2001), leading to the view that the alpha 1 subtype is more involved in sedation than in sleep.”
BackgroundROTH, T., WALSH, J., KRYSTAL, A., WESSEL, T., & ROEHRS, T. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.06.004 · Cited by 230 · cited 5×
“Eszopiclone’s sleep and next-day function improvements are sustained over 6–12 months (Krystal et al., 2003; Roth et al., 2005; Walsh et al., 2007) and there is no significant evidence of tolerance, dependence or rebound insomnia during and after long-term treatment (Zammit et al., 2004; Roth et…”
BackgroundResultInfluentialA multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf, M. B., Roth, T. G., Vogel, G. W., & Walsh, J. K. (1994) · PubMed · Cited by 223
Gao, B., Fritschy, J. M., Benke, D., & Mohler, H. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90582-z · Cited by 214 · cited 1×
“The anxiolytic effects of alpha 3-selective GABA receptor agonists may be mediated by activation of GABAA receptors located on monoaminergic cells in the dorsal raphe nucleus (Gao et al., 1993; Langen and Rundfeldt, 2007).”
BackgroundKrystal, A. D., Erman, M., Zammit, G. K., Soubrane, C., & Roth, T. (2008) · Sleep · doi:10.1093/sleep/31.1.79 · Cited by 212
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes
Sanna, E., Busonero, F., Talani, G., Carta, M., Massa, F., Peis, M., Maciocco, E., & Biggio, G. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02191-x · Cited by 208 · cited 6×
“…effects is relatively scarce, but it appears that zaleplon binds preferentially to alpha 1-containing GABAA receptors (Noguchi et al., 2002; King Pharmaceuticals, 2006; Wegner et al., 2008), and may be considered alpha 1-selective (Sanna et al., 2002; Petroski et al., 2006) (Figure 1A and Table 2).”
BackgroundMethodInfluentialElie, R., Ruther, E., Farr, I., Emilien, G., Salinas, E., & The Zaleplon Clinical Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0806 · Cited by 191 · cited 2×
“Zaleplon improves sleep latency but not sleep duration (Elie et al., 1999) (Table 6), and so is an appropriate choice for patients whose primary complaint is difficulty falling asleep but not for patients with sleep maintenance difficulties (Drover, 2004).”
BackgroundAtack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188 · cited 1×
“Furthermore GABAA agonists with selectivity for alpha 2 and alpha 3 subtypes are anxiolytic in rodents and in primates, without having sedative or adverse cognitive effects (Licata et al., 2005; Atack et al., 2006; de Haas et al., 2007).”
BackgroundGABAA Receptors: Subtypes, Regional Distribution, and Function
Nutt, D. J. (2006) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26525 · Cited by 180
Self-citationZolpidem for Persistent Insomnia in SSRI-Treated Depressed Patients
Asnis, G. M., Chakraburtty, A., DuBoff, E. A., Krystal, A., Londborg, P. D., Rosenberg, R., Roth-Schechter, B., Scharf, M. B., & Walsh, J. K. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1005 · Cited by 176 · cited 1×
“In contrast, zolpidem/SSRI co-therapy is not associated with any additional antidepressant benefits over SSRI monotherapy as measured by the HAM-D17 scale (Asnis et al., 1999; Fava et al., 2008).”
MethodTreating insomnia: Current and investigational pharmacological approaches
Ebert, B., Wafford, K. A., & Deacon, S. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.014 · Cited by 166 · cited 2×
“(2008) obtained from adult rat cerebellum (predominantly alpha 1) and neonatal rat whole brain (predominantly alpha 2 and alpha 3) tissue (Fleck, 2002; Sanna et al., 2002; Ebert et al., 2006; Petroski et al., 2006; Wegner et al., 2008; Brunello et al., 2009).”
BackgroundMethodEight Weeks of Non-Nightly Use of Zolpidem for Primary Insomnia
Walsh, J. K., Roth, T., Randazzo, A., Erman, M., Jamieson, A., Scharf, M., Schweitzer, P. K., & Ware, J. C. (2000) · Sleep · doi:10.1093/sleep/23.8.1h · Cited by 158 · cited 2×
“However, the short t½ explains zaleplon’s lack of residual effects (Fry et al., 2000; Walsh et al., 2000a; Stone et al., 2002), and means that zaleplon is the only hypnotic indicated for taking after the patient has gone to bed and has experienced difficulty falling asleep (Walsh et al., 2000a).”
BackgroundPollack, M., Kinrys, G., Krystal, A., McCall, W. V., Roth, T., Schaefer, K., Rubens, R., Roach, J., Huang, H., & Krishnan, R. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.551 · Cited by 158 · cited 4×
“In a study of patients with insomnia co-morbid with GAD, zolpidem CR/escitalopram co-therapy resulted in significant sleep improvements compared with monotherapy.”
BackgroundResultInfluentialLong-Term, Non-Nightly Administration of Zolpidem in the Treatment of Patients With Primary Insomnia
Perlis, M. L., McCall, W. V., Krystal, A. D., & Walsh, J. K. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0816 · Cited by 144 · cited 1×
“Zolpidem IR improves sleep latency and has shown inconsistent effects on sleep maintenance (Scharf et al., 1994; Monti et al., 1996; Walsh et al., 2000b; Perlis et al., 2004) (Table 6).”
Backgroundvan Rijnsoever, C., Täuber, M., Choulli, M. K., Keist, R., Rudolph, U., Mohler, H., Fritschy, J. M., & Crestani, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1067-04.2004 · Cited by 144 · cited 1×
“Finally, some evidence suggests alpha 5 receptor agonists may have sedative effects (van Rijnsoever et al., 2004; Savić et al., 2008).”
BackgroundA 2-Week Efficacy and Safety Study of Eszopiclone in Elderly Patients with Primary Insomnia
Scharf, M., Erman, M., Rosenberg, R., Seiden, D., McCall, W. V., Amato, D., & Wessel, T. C. (2005) · Sleep · doi:10.1093/sleep/28.6.720 · Cited by 143 · cited 1×
“Eszopiclone significantly improves objective measures of sleep versus placebo (Zammit et al., 2004; Scharf et al., 2005; McCall et al., 2006) (Table 6).”
BackgroundAnxiogenic properties of an inverse agonist selective for α 3 subunit‐containing GABAA receptors
Atack, J. R., Hutson, P. H., Collinson, N., Marshall, G., Bentley, G., Moyes, C., Cook, S. M., Collins, I., Wafford, K., McKernan, R. M., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706056 · Cited by 134 · cited 2×
“Alpha 3-selective inverse agonism is anxiogenic in mice (Atack et al., 2005), whereas selective alpha 3 agonism is anxiolytic in mice and primates (Dias et al.”
BackgroundModulation of rhythmic brain activity by diazepam: GABA A receptor subtype and state specificity
Kopp, C., Rudolph, U., Löw, K., & Tobler, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306975101 · Cited by 133 · cited 3×
“Mice with point-mutated alpha 2 GABA receptor subunits lack an anxiolytic response to diazepam (Löw et al., 2000) and examination of a murine knock-in has shown that the anxiolytic effect of benzodiazepines is mediated by alpha 2 receptors expressed in the limbic system (Kopp et al., 2004).”
BackgroundPetroski, R. E., Pomeroy, J. E., Das, R., Bowman, H., Yang, W., Chen, A. P., & Foster, A. C. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.096701 · Cited by 128 · cited 4×
“As zopiclone has similar efficacy at alpha 1, alpha 2, alpha 3 and alpha 5 receptors (Petroski et al., 2006; Brunello et al., 2009) (Figure 1C), differences in binding will determine its effects in vivo.”
BackgroundInfluentialEmerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time
Wafford, K. A., & Ebert, B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2464 · Cited by 123 · cited 4×
“Furthermore, improvements in next-day functioning and quality of life are also desirable in hypnotic therapies (Wafford and Ebert, 2008).”
BackgroundInfluentialNutt, D. J., Besson, M. J., Wilson, S. J., Dawson, G. R., & Lingford-Hughes, A. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.008 · Cited by 123 · cited 2×
“Alpha 5 inverse agonists, which reduce GABA-mediated neurotransmission through this receptor, inhibit the amnestic effects of alcohol in humans (Nutt et al., 2007), and enhance cognition, learning and memory in rodents (Collinson et al.”
BackgroundSelf-citation(2002) · Sleep · doi:10.1093/sleep/25.2.224 · Cited by 122 · cited 2×
“Racemic zopiclone’s utility may be limited by its potential for residual next-day effects and known associations with impaired driving ability (Bocca and Denise, 2000; Isawa et al., 2000; Vermeeren et al., 2002; Staner et al., 2005).”
BackgroundRoth, T. G., Soubrane, C., Titeux, L., & Walsh, J. K. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.04.008 · Cited by 121 · cited 2×
“As many as 80% of patients with insomnia report comorbid psychiatric symptoms (Stewart et al., 2006), and insomnia is known to be a risk factor for both depression and anxiety disorders (Roth et al., 2006a; Janssen-Fröjmark and Lindblom, 2008).”
BackgroundLingford-Hughes, A., Hume, S. P., Feeney, A., Hirani, E., Osman, S., Cunningham, V. J., Pike, V. W., Brooks, D. J., & Nutt, D. J. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200207000-00013 · Cited by 112
Self-citationNajib, J. S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.014 · Cited by 110 · cited 1×
“Eszopiclone is the pure (S)-enantiomer of racemic zopiclone (Najib, 2006), and was licensed in the USA in December 2004 but it is not currently available in Europe.”
Backgroundde Haas, S. L., de Visser, S. J., van der Post, J. P., Schoemaker, R. C., van Dyck, K., Murphy, M. G., de Smet, M., Vessey, L. K., Ramakrishnan, R., Xue, L., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107082108 · Cited by 104
A polysomnography study of eszopiclone in elderly patients with insomnia
Vaughn McCall, W., Erman, M., Krystal, A. D., Rosenberg, R., Scharf, M., Zammit, G. K., & Wessel, T. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112741 · Cited by 97 · cited 1×
“Eszopiclone significantly improves objective measures of sleep versus placebo (Zammit et al., 2004; Scharf et al., 2005; McCall et al., 2006) (Table 6).”
BackgroundBrowne, S. H., Kang, J., Akk, G., Chiang, L. W., Schulman, H., Huguenard, J. R., & Prince, D. A. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.5.2312 · Cited by 96 · cited 2×
“Of particular importance to sleep is the unique distribution of alpha 3 subtype receptors in the thalamus (Pirker et al., 2000), where they mediate GABAA inhibition in the reticular nucleus (Browne et al., 2001).”
BackgroundZaleplon improves sleep without producing rebound effects in outpatients with insomnia
Fry, J., Scharf, M., Mangano, R., & Fujimori, M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00003 · Cited by 93 · cited 2×
“Lunesta Prescribing Information (available at http://www.lunesta.com/). symptoms have been seen after treatment discontinuation in pivotal trials (Elie et al., 1999; Fry et al., 2000; Stone et al., 2002).”
BackgroundMonti, J., Attali, P., Monti, D., Zipfel, A., de la Giclais, B., & Morselli, P. (1994) · Pharmacopsychiatry · doi:10.1055/s-2007-1014298 · Cited by 92 · cited 2×
“, 1994) and tolerance and rebound insomnia have been reported (Monti et al., 1994; Ware et al., 1997; Roth et al., 2006b).”
BackgroundKrystal, A., Fava, M., Rubens, R., Wessel, T., Caron, J., Wilson, P., Roth, T., & McCall, W. V. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26745 · Cited by 90 · cited 2×
“Furthermore, the sleep and mood benefits observed in the eszopiclone/fluoxetine co-therapy group versus the monotherapy group persisted after discontinuation of eszopiclone (Krystal et al., 2007).”
BackgroundWalsh, J. K., Pollak, C. P., Scharf, M. B., Schweitzer, P. K., & Vogel, G. W. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00004 · Cited by 88 · cited 2×
“However, the short t½ explains zaleplon’s lack of residual effects (Fry et al., 2000; Walsh et al., 2000a; Stone et al., 2002), and means that zaleplon is the only hypnotic indicated for taking after the patient has gone to bed and has experienced difficulty falling asleep (Walsh et al., 2000a).”
Backgroundde Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84 · cited 1×
“Furthermore GABAA agonists with selectivity for alpha 2 and alpha 3 subtypes are anxiolytic in rodents and in primates, without having sedative or adverse cognitive effects (Licata et al., 2005; Atack et al., 2006; de Haas et al., 2007).”
BackgroundStaner, L., Ertle, S., Boeijinga, P. H., Rinaudo, G., Arnal, M. A., Muzet, A. G., & Luthringer, R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0082-8 · Cited by 81 · cited 2×
“Racemic zopiclone’s utility may be limited by its potential for residual next-day effects and known associations with impaired driving ability (Bocca and Denise, 2000; Isawa et al., 2000; Vermeeren et al., 2002; Staner et al., 2005).”
BackgroundGABAA receptor subtype selectivity underlying selective anxiolytic effect of baicalin
Wang, F., Xu, Z., Ren, L., Tsang, S. Y., & Xue, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.040 · Cited by 81 · cited 1×
“A compound with similar high alpha 1 affinity, but functional selectivity for alpha 2 and 3, has shown anxiolytic effects (Wang et al., 2008) and, based on its binding and activity profile, eszopiclone would be expected to provide both hypnotic and anxiolytic benefits at similar dose levels.”
BackgroundMechanisms of sleep induction by GABA(A) receptor agonists.
Harrison, N. L. (2007) · PubMed · Cited by 79
Savić, M. M., Huang, S., Furtmüller, R., Clayton, T., Huck, S., Obradovic, D. I., Ugrešić, N. D., Sieghart, W., Bokonjić, D. R., & Cook, J. M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301403 · Cited by 78 · cited 1×
“Finally, some evidence suggests alpha 5 receptor agonists may have sedative effects (van Rijnsoever et al., 2004; Savić et al., 2008).”
BackgroundPharmacological and clinical studies of cyclopyrrolones: Zopiclone and suriclone
Julou, L., Blanchard, J. C., & Dreyfus, J. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90433-2 · Cited by 76
Minimal Rebound Insomnia After Treatment with 10-mg Zolpidem
Ware, J. C., Walsh, J. K., Scharf, M. B., Roehrs, T., Roth, T., & Vogel, G. W. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199704000-00002 · Cited by 75 · cited 2×
“, 1994) and tolerance and rebound insomnia have been reported (Monti et al., 1994; Ware et al., 1997; Roth et al., 2006b).”
BackgroundSedative and anxiolytic effects of zopiclone's enantiomers and metabolite
Carlson, J. N., Haskew-Layton, R. E., Wacker, J. L., Maisonneuve, I. M., Glick, S. D., & Jerussi, T. P. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00851-2 · Cited by 74 · cited 1×
“Measurable plasma concentrations of both SDMZ and (R)-zopiclone are present 8 hours after zopiclone dosing and could contribute to unwanted next-day residual effects (Carlson et al., 2001).”
BackgroundEfficacy and Safety of Zolpidem Extended Release in Elderly Primary Insomnia Patients
Walsh, J. K., Soubrane, C., & Roth, T. G. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181256b01 · Cited by 74 · cited 1×
“Zolpidem CR is a more rational choice for improving sleep duration (Weinling et al., 2006; Krystal et al., 2008a; Walsh et al., 2008) but is not currently available in Europe.”
BackgroundRosenberg, R. P., Caron, J., Roth, T. G., & Amato, D. A. (2004) · Sleep Medicine · doi:10.1016/j.sleep.2004.09.001 · Cited by 69 · cited 1×
“In contrast to findings reported for racemic zopiclone, eszopiclone provides benefits in next-day functioning and alertness (Krystal et al., 2003; Rosenberg et al., 2005; Roth et al., 2005; Scharf, 2006).”
ResultPharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers.
Fernandez, C., Maradeix, V, Gimenez, F., Thuillier, A., & Farinotti, R. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08209-1 · Cited by 53 · cited 2×
“Zopiclone is a racemic mixture of (S)- and (R)-isomers, with stereoselective PK profiles (Fernandez et al., 1993, 2002) and clinical outcomes (McMahon et al., 2003).”
BackgroundBoyle, J., Trick, L., Johnsen, S., Roach, J., & Rubens, R. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.936 · Cited by 51 · cited 1×
“Furthermore, eszopiclone does not appear to affect next-day driving skills (Boyle et al., 2008).”
BackgroundMonti, J. M., Monti, D., Estévez, F., & Giusti, M. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199612000-00007 · Cited by 49 · cited 1×
“Zolpidem IR improves sleep latency and has shown inconsistent effects on sleep maintenance (Scharf et al., 1994; Monti et al., 1996; Walsh et al., 2000b; Perlis et al., 2004) (Table 6).”
BackgroundDockhorn, R. J., & Dockhorn, D. W. (1996) · Clinical Neuropharmacology · doi:10.1097/00002826-199619040-00006 · Cited by 48 · cited 2×
“However, zolpidem IR and CR use does not appear to be associated with nextday residual impairments compared with placebo (Dockhorn and Dockhorn, 1996; Krystal et al., 2008a) and zolpidem IR has been associated with improvements in next-day function (Scharf et al.”
BackgroundWeinling, E., McDougall, S. A., Andre, F., Bianchetti, G., & Dubruc, C. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00415.x · Cited by 46
Bailey, J., Papadopoulos, A., Seddon, K., & Nutt, D. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089603 · Cited by 46 · cited 1×
“A single recent study of zolpidem in a CO2-induced model of generalized anxiety disorder (GAD) in human volunteers demonstrated some anxiolytic efficacy of zolpidem, although this was less than that seen with a nonselective benzodiazepine (Bailey et al., 2009).”
BackgroundSelf-citationLicata, S. C., Platt, D. M., Cook, J. M., Sarma, P., Griebel, G., & Rowlett, J. K. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081612 · Cited by 43 · cited 1×
“Furthermore GABAA agonists with selectivity for alpha 2 and alpha 3 subtypes are anxiolytic in rodents and in primates, without having sedative or adverse cognitive effects (Licata et al., 2005; Atack et al., 2006; de Haas et al., 2007).”
BackgroundTsutsui, S., & Zolpidem Study Group (2001) · Journal of International Medical Research · doi:10.1177/147323000102900303 · Cited by 35
Noise‐induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon
Stone, B. M., Turner, C., Mills, S. L., Paty, I., Patat, A., Darwish, M., & Danjou, P. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.-5251.2001.01520.x · Cited by 34 · cited 4×
“symptoms have been seen after treatment discontinuation in pivotal trials (Elie et al., 1999; Fry et al., 2000; Stone et al., 2002).”
BackgroundInfluentialInsomnia: Principles and Management
Zisapel, N. (2004) · BMJ · doi:10.1136/bmj.328.7430.55-a · Cited by 32 · cited 1×
“The PK profile may be more critical for a hypnotic drug in the treatment of insomnia than for any other drug in psychiatry (Szuba et al., 2003; Drover, 2004).”
BackgroundA Double-blind Placebo-controlled Trial of Zopiclone 7·5 mg and Temazepam 20 mg in Insomnia
NGEN, C. C., & HASSAN, R. (1990) · International Clinical Psychopharmacology · doi:10.1097/00004850-199007000-00001 · Cited by 30 · cited 1×
“Racemic zopiclone reduces sleep latency and increases total sleep time (TST) (Ngen and Hassan, 1990; Ponciano et al., 1990; Noble et al., 1998; Sivertsen et al., 2006) (Table 6).”
BackgroundBinding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic
Noguchi, H., Kitazumi, K., Mori, M., & Shiba, T. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01502-3 · Cited by 28 · cited 2×
“Information on zaleplon’s pharmacodynamic effects is relatively scarce, but it appears that zaleplon binds preferentially to alpha 1-containing GABAA receptors (Noguchi et al., 2002; King Pharmaceuticals, 2006; Wegner et al., 2008), and may be considered alpha 1-selective (Sanna et al.”
BackgroundPonciano, E., Freitas, F., Camara, J., Faria, M. H. C. P., Barreto, M., & Hindmarch, I. (1990) · PubMed · Cited by 27
Insomnia : principles and management
Szuba, M. P., Kloss, J. D., & Dinges, D. F. (2003) · Cited by 27
Fernandez, C., Alet, P., Davrinche, C., Adrien, J., Thuillier, A., Farinotti, R., & Gimenez, F. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778574 · Cited by 27 · cited 1×
“Zopiclone is a racemic mixture of (S)- and (R)-isomers, with stereoselective PK profiles (Fernandez et al., 1993, 2002) and clinical outcomes (McMahon et al., 2003).”
BackgroundMolecular Actions of (S)-Desmethylzopiclone (SEP-174559), an Anxiolytic Metabolite of Zopiclone
Fleck, M. W. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033886 · Cited by 27 · cited 1×
“…et al. (2008) obtained from adult rat cerebellum (predominantly alpha 1) and neonatal rat whole brain (predominantly alpha 2 and alpha 3) tissue (Fleck, 2002; Sanna et al., 2002; Ebert et al., 2006; Petroski et al., 2006; Wegner et al., 2008; Brunello et al., 2009). aFunctional effect was…”
BackgroundFiorelli, R., Rudolph, U., Straub, C. J., Feldon, J., & Yee, B. K. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830dc0c7 · Cited by 26 · cited 1×
“In addition, studies of alpha 3 knockout mice suggest a potential antidepressant role of this receptor subtype (Fiorelli et al., 2008).”
BackgroundWegner, F., Deuther‐Conrad, W., Scheunemann, M., Brust, P., Fischer, S., Hiller, A., Diekers, M., Strecker, K., Wohlfarth, K., Allgaier, C., et al. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.10.016 · Cited by 26 · cited 5×
“Information on zaleplon’s pharmacodynamic effects is relatively scarce, but it appears that zaleplon binds preferentially to alpha 1-containing GABAA receptors (Noguchi et al., 2002; King Pharmaceuticals, 2006; Wegner et al., 2008), and may be considered alpha 1-selective (Sanna et al.”
BackgroundMethodInfluentialMathiasen, L., Rodgers, R. J., & Mirza, N. R. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32814fcdd4 · Cited by 24 · cited 1×
“When affinity, potency and efficacy are considered as a whole, zolpidem’s clinical effects would appear to be mediated primarily via the alpha 1 receptor subtype (Table 2) and thus zolpidem might not be expected to provide anxiolytic benefits (Mathiasen et al., 2007).”
BackgroundBenzodiazepine Hypnotics and Insomnia
Kales, A. (1990) · Hospital Practice · doi:10.1080/21548331.1990.11704103 · Cited by 23 · cited 1×
“These drugs all offer improved tolerability compared with previous insomnia therapies, the benzodiazepines (Kales, 1990; Holbrook et al., 2000), and recent studies have provided evidence for Z-drug efficacy over the long-term and across different patient populations.”
BackgroundLong-term, Non-nightly Administration of Zolpidem in the Treatment of Patients With Primary Insomnia
Ballenger, J. (2006) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70258-5 · Cited by 21
Mamelak, M., Buck, L., Csima, A., Price, V., & Smiley, A. M. (1987) · SLEEP · doi:10.1093/sleep/10.suppl_1.79 · Cited by 19
Eszopiclone for the treatment of insomnia
Scharf, M. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.3.345 · Cited by 15 · cited 1×
“In contrast to findings reported for racemic zopiclone, eszopiclone provides benefits in next-day functioning and alertness (Krystal et al., 2003; Rosenberg et al., 2005; Roth et al., 2005; Scharf, 2006).”
ResultThe effect of zolpidem and zopiclone on memory.
Isawa, S., Suzuki, M., UCHIUMI, M., & Murasaki, M. (2000) · PubMed · Cited by 14
Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys
McMahon, L. R., Jerussi, T. P., & France, C. P. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1286-9 · Cited by 14 · cited 2×
“, 1993, 2002) and clinical outcomes (McMahon et al., 2003).”
BackgroundCalming the Brain: Benzodiazepines and related drugs from laboratory to clinic
Doble, A., Martin, I. L., & Nutt, D. J. (2020) · CRC Press eBooks · doi:10.4324/9781003076407 · Cited by 11 · cited 1×
“They are involved in GABA-mediated inhibition and also mediate the sedative, anxiolytic, muscle relaxant and anticonvulsant effects of drugs such as benzodiazepines and the Z-drugs (Doble et al., 2004).”
BackgroundSelf-citationResidual effects of hypnotics on disengagement of spatial attention
Bocca, M., & Denise, P. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400409 · Cited by 9 · cited 1×
“Racemic zopiclone’s utility may be limited by its potential for residual next-day effects and known associations with impaired driving ability (Bocca and Denise, 2000; Isawa et al., 2000; Vermeeren et al., 2002; Staner et al., 2005).”
BackgroundBrunello, N., Bettica, P. U., Amato, D., Maier, G. A., & Nutt, D. (2008) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(08)70890-3 · Cited by 7 · cited 2×
“Levels of SDMZ are detectable at this time but are lower than those seen after an equivalently effective dose of racemic zopiclone (Brunello et al., 2008), suggesting that use of the single-isomer drug may reduce the risk of residual effects compared with the parent compound.”
BackgroundSelf-citationLangen, B., & Rundfeldt, C. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.12.010 · Cited by 4 · cited 1×
“The anxiolytic effects of alpha 3-selective GABA receptor agonists may be mediated by activation of GABAA receptors located on monoaminergic cells in the dorsal raphe nucleus (Gao et al., 1993; Langen and Rundfeldt, 2007).”
Background
Research works printed but not linked: 18
- Brunello N., Abstract Presented at the World Psychiatric Association International Congress (WPA-Florence)
- Fava M., Presented at 46th Annual Meeting of the American College of Neuropsychopharmacology
- Fava M., Presented at the American Psychiatric Association (APA) 161st Annual Meeting
- Harrison NL, 2007, J Clin Psychia, 68, 6
- Holbrook AM, 2000, Can Med Ass J, 162, 225
- Isawa S., 2000, Nihon Shinkei Seishin Yakurigaku Zasshi, 20, 61
- Krystal A., 2008, Euro Neuropsychopharmacol, 18, S517
- Krystal A., 2008, Eur Neuropsychopharmacol, 18, S517
- Krystal AD, 2007, Journal of Clinical Sleep Medicine, 3, 48
- Meda Pharmaceuticals, 2008, Sonata SPC (online)
- Ponciano E., 1990, Int Clin Psychopharmacol, 5, 69
- Roth T., 2007, Journal of Clinical Sleep Medicine, 3, S7
- Sanofi-Aventis., 2007, Ambien (Zolpidem Tartrate) Tablets for Oral Administration Prescribing Information
- Sanofi Aventis, 2008, Stilnoct SPC
- Sanofi-Aventis, 2008, Zimovane SPC
- Scharf MB, 1994, J Clin Psychiat, 55, 192
- Sepracor., 2007, Lunesta (Eszopiclone) Tablets Prescribing Information
- Vermeeren A., 2002, Sleep, 25, 224
Cited by
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
“Although there have been no head-to-head studies addressing this question, there is some lower level evidence in humans that subtype selective drugs such as eszopiclone produce less tolerance and rebound (Krystal et al., 2003; Nutt and Stahl, 2009).”
BackgroundSelf-citationThe GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
“When affinity, potency and efficacy are taken into account, eszopiclone can be considered to act preferentially via a2, a3 receptors, with a1 GABAA receptors contributing possibly at higher doses (Nutt and Stahl, 2010; Jia et al., 2009).”
BackgroundDe Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00878-9 · Cited by 446
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
“Zaleplon, zopiclone, and zolpidem have high affinity and potency for the a1 subunit and low affinity and potency at a2 and a3 subunits; eszopiclone—the (S)-enantiomer of zopiclone —has high affinity and potency for the a2 and a3 subunits (Nutt and Stahl, 2010).”
Background
Metadata
- Authors
- Nutt, D. J., & Stahl, S. M.
- Affiliations
- Imperial College London (GB)
- University of California San Diego (US)
- Corresponding author
- Nutt, David J
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-11-26
- Volume
- 24
- Issue
- 11
- Pages
- 1601-1612
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2008821456
- Cited by
- 163
- References
- 98
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 9 · 2019: 11 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 6 · 2014: 22 · 2013: 14 · 2012: 15
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Keywords
- GABA-A receptor modulators, Z-drugs, hypnotics, insomnia, zaleplon, zolpidem, zopiclone, eszopiclone, selective serotonin reuptake inhibitors, psychiatric comorbidity, GABAA receptor subtypes, alpha1 subunit, alpha2 subunit, alpha3 subunit, functional selectivity, pharmacokinetics, sedative effects, anxiolytic effects, antidepressant effects, drug tolerability
- MeSH terms
- Clinical Trials as Topic, Drug Therapy, Combination, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Receptors, GABA-A, Sleep, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.